Pharmaconutrition for the obese, critically ill patient

Journal of Parenteral and Enteral Nutrition

Volumn 35, Issue 5 SUPPL., 2011, Pages

  Hurt, Ryan T ^a,c   Frazier, Thomas H ^a,b   McClave, Stephen A ^a,b   Cave, Matt C ^a,b  

^a Department of Medicine ^*  (United States)

^b University of Louisville School of Medicine   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Obesity; Pharmaconutrition; Prebiotics; Probiotics

Indexed keywords

ARGININE; CITRULLINE; CURCUMIN; GREEN TEA EXTRACT; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LEUCINE; MAGNESIUM; MEDIUM CHAIN TRIACYLGLYCEROL; POLYUNSATURATED FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; SOYBEAN PROTEIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ZINC; ANTIOXIDANT; UNSATURATED FATTY ACID;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CRITICALLY ILL PATIENT; ENTERIC FEEDING; HUMAN; LIPOTOXICITY; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TEA; AIR CONDITIONING; CRITICAL ILLNESS; DIET SUPPLEMENTATION; ENTERITIS; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; METHODOLOGY; PROTEIN INTAKE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANTIOXIDANTS; ARGININE; CITRULLINE; CRITICAL CARE; CRITICAL ILLNESS; DIETARY PROTEINS; DIETARY SUPPLEMENTS; ENTERAL NUTRITION; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATORY BOWEL DISEASES; INTENSIVE CARE UNITS; LENGTH OF STAY; LEUCINE; MAGNESIUM; OBESITY; OXIDATIVE STRESS; PREBIOTICS; PROBIOTICS; TREATMENT OUTCOME; UNITED STATES; VENTILATION; ZINC;

EID: 84855388899     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607111413775     Document Type: Article

References (124)

1. Heyland DK. Nutritional support in the critically ill patients: a critical review of the evidence. Crit Care Clin. 1998;14(3):423-440.
2. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition. 2004;20(10):843-848.
3. Montejo JC, Zarazaga A, Lopez-Martinez J, et al. Immunonutrition in the intensive care unit: a systematic review and consensus statement. Clin Nutr. 2003;22(3):221-233.
4. Serrano PE, Khuder SA, Fath JJ. Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg. 2010;211(1):61-67.
5. Neville AL, Brown CV, Weng J, Demetriades D, Velmahos GC. Obesity is an independent risk factor of mortality in severely injured blunt trauma patients. Arch Surg. 2004;139(9):983-987.
6. Winfield RD, Delano MJ, Dixon DJ, et al. Differences in outcome between obese and nonobese patients following severe blunt trauma are not consistent with an early inflammatory genomic response. Crit Care Med. 2010;38(1):51-58.
7. Cave MC, Hurt RT, Frazier TH, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008;23(1):16-34.
8. Matheson PJ, Hurt RT, Franklin GA, McClain CJ, Garrison RN. Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock. Surgery. 2009;146(4):739- 747; discussion 747-748.
9. Levi D, Goodman ER, Patel M, Savransky Y. Critical care of the obese and bariatric surgical patient. Crit Care Clin. 2003;19(1):11-32.
10. Hurt RT, Frazier TH, Matheson PJ, et al. Obesity and inflammation: III. Curr Gastroenterol Rep. 2007;9(4):307-308.
11. Hurt RT, Frazier TH, Matheson PJ, et al. Obesity and inflammation: II. Curr Gastroenterol Rep. 2007;9(4):306-307.
12. Hurt RT, Frazier TH, Matheson PJ, et al. Obesity and inflammation: should the principles of immunonutrition be applied to this disease process? Curr Gastroenterol Rep. 2007;9(4):305-306.
13. Wang H, Khor TO, Saw CL, et al. Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol Pharm. 2010;7(6):2185-2193.
14. Hurt RT, Matheson PJ, Mays MP, Garrison RN. Immuneenhancing diet and cytokine expression during chronic sepsis: an immune-enhancing diet containing L-arginine, fish oil, and RNA fragments promotes intestinal cytokine expression during chronic sepsis in rats. J Gastrointest Surg. 2006;10(1):46-53.
15. Layman DK. The role of leucine in weight loss diets and glucose homeostasis. J Nutr. 2003;133(1):261S-267S.
16. Layman DK, Clifton P, Gannon MC, Krauss RM, Nuttall FQ. Protein in optimal health: heart disease and type 2 diabetes. Am J Clin Nutr. 2008;87(5):1571S-1575S.
17. Matheson PJ, Harris BT, Hurt RT, Zakaria ER, Garrison RN. Enteral glutamine supplementation impairs intestinal blood flow in rats. Am J Surg. 2008;196(2):293-299.
18. Matheson PJ, Hurt RT, Mittel OF, Wilson MA, Spain DA, Garrison RN. Immune-enhancing enteral diet increases blood flow and proinflammatory cytokines in the rat ileum. J Surg Res. 2003;110(2):360-370.
19. Pi J, Leung L, Xue P, et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J Biol Chem. 2010;285(12):9292-9300.
20. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008;74(13):1526-1539.
21. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-3558.
22. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010;30:173-199.
23. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G20-G30.
24. Ohara K, Uchida A, Nagasaka R, Ushio H, Ohshima T. The effects of hydroxycinnamic acid derivatives on adiponectin secretion. Phytomedicine. 2009;16(2-3):130-137.
25. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270(42):24995-25000.
26. Saw CL, Huang Y, Kong AN. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. 2010;79(3):421-430.
27. Dinkova-Kostova AT, Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res. 2008;52(suppl 1):S128-S138.
28. Brandenburg LO, Kipp M, Lucius R, Pufe T, Wruck CJ. Sulforaphane suppresses LPS-induced inflammation in primary rat microglia. Inflamm Res. 2010;59(6):443-450.
29. Lin W, Wu RT, Wu T, Khor TO, Wang H, Kong AN. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol. 2008;76(8):967-973.
30. Kim YW, Kim YM, Yang YM, et al. Inhibition of LXRalphadependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. Antioxid Redox Signal. 2011;14(5):733-745.
31. Kay HY, Won Yang J, Kim TH, et al. Ajoene, a stable garlic byproduct, has an antioxidant effect through Nrf2-mediated glutamate- cysteine ligase induction in HepG2 cells and primary hepatocytes. J Nutr. 2010;140(7):1211-1219.
32. Tanigawa S, Fujii M, Hou DX. Action of Nrf2 and Keap1 in AREmediated NQO1 expression by quercetin. Free Radic Biol Med. 2007;42(11):1690-1703.
33. Grove KA, Lambert JD. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr. 2010;140(3):446-453.
34. Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med. 2010;5:13.
35. Furuyashiki T, Nagayasu H, Aoki Y, et al. Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPARgamma2 and C/EBPalpha in 3T3-L1 cells. Biosci Biotechnol Biochem. 2004;68(11):2353-2359.
36. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res. 2006;50(2):176-187.
37. Wolfram S, Raederstorff D, Wang Y, Teixeira SR, Elste V, Weber P. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann Nutr Metab. 2005;49(1):54-63.
38. Kobayashi Y, Suzuki M, Satsu H, et al. Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem. 2000;48(11):5618-5623.
39. Ashida H, Furuyashiki T, Nagayasu H, et al. Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors. 2004;22(1-4):135-140.
40. Shimada M, Mochizuki K, Sakurai N, Goda T. Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem. 2007;71(8):2079-2082.
41. Yun JM, Jialal I, Devaraj S. Effects of epigallocatechin gallate on regulatory T cell number and function in obese v. lean volunteers. Br J Nutr. 2010;103(12):1771-1777.
42. Wu D, Guo Z, Ren Z, Guo W, Meydani SN. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med. 2009;47(5):636-643.
43. Kim JA, Formoso G, Li Y, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem. 2007;282(18):13736-13745.
44. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab. 2007;292(5):E1378- E1387.
45. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol. 2010;48(1):409-416.
46. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009;65(4):331-341.
47. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008;34(11):1980-1990.
48. Bays HE. "Sick fat," metabolic disease, and atherosclerosis. Am J Med. 2009;122(1)(suppl):S26-S37.
49. Bays HE, Maki KC, Doyle RT, Stein E. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Postgrad Med. 2009;121(5):145-150.
50. Akhavan T, Luhovyy BL, Anderson GH. Effect of drinking compared with eating sugars or whey protein on short-term appetite and food intake. Int J Obes (Lond). 2011;35:562-569.
51. Takayama F, Nakamoto K, Totani N, et al. Effects of docosahexaenoic acid in an experimental rat model of nonalcoholic steatohepatitis. J Oleo Sci. 2010;59(8):407-414.
52. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23(8):1143-1151.
53. Duda MK, O'Shea KM, Lei B, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovas Res. 2007;76(2):303-310.
54. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem. 2008;19(9):567-576.
55. Nanji AA, Sadrzadeh SM, Yang EK, Fogt F, Meydani M, Dannenberg AJ. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology. 1995;109(2):547-554.
56. Polavarapu R, Spitz DR, Sim JE, et al. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology. 1998;27(5):1317-1323.
57. Ronis MJ, Korourian S, Zipperman M, Hakkak R, Badger TM. Dietary saturated fat reduces alcoholic hepatotoxicity in rats by altering fatty acid metabolism and membrane composition. J Nutr. 2004;134(4):904-912.
58. Nanji AA, Jokelainen K, Lau GK, et al. Arginine reverses ethanolinduced inflammatory and fibrotic changes in liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299(3):832-839.
59. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology. 2006;147(2):943-951.
60. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006;291(2):E275-E281.
61. Nanji AA, Mendenhall CL, French SW. Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res. 1989;13(1):15-19.
62. Nanji AA, Tsukamoto H, French SW. Relationship between fatty liver and subsequent development of necrosis, inflammation and fibrosis in experimental alcoholic liver disease. Exp Mol Pathol. 1989;51(2):141-148.
63. Wu G, Bazer FW, Cudd TA, et al. Pharmacokinetics and safety of arginine supplementation in animals. J Nutr. 2007;137(6)(suppl 2):1673S-1680S.
64. Wu G, Bazer FW, Davis TA, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37(1):153-168.
65. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(6):609-615.
66. Onat A, Hergenc G. Reduced asymmetric dimethylarginine (ADMA) levels mediate in the protection from metabolic syndrome by smoking. Atherosclerosis. 2008;196(1):479-480.
67. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010;77(1):44-50.
68. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res. 2009;60(6):508-514.
69. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab. 2006;91(5):1896-1900.
70. Guttman H, Zimlichman R, Boaz M, Matas Z, Shargorodsky M. Effect of Long-term L-arginine supplementation on arterial compliance and metabolic parameters in patients with multiple cardiovascular risk factors: randomized, placebo-controlled study. J Cardiovasc Pharmacol. 2010 Jun 7. [Epub ahead of print]
71. Lucotti P, Monti L, Setola E, et al. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism. 2009;58(9):1270-1276.
72. Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit. 2010;16(5):CR266-CR271.
73. Lu WM, Lei ST, Zhang Q, Zhang YJ, Wang SM, Shi HP. Effect of L-arginine on diabetic rats [in Chinese]. Nan fang yi ke da xue xue bao. 2006;26(10):1434-1435, 1445.
74. Fu WJ, Haynes TE, Kohli R, et al. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr. 2005;135(4):714-721.
75. Lucotti P, Setola E, Monti LD, et al. Beneficial effects of a longterm oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006;291(5):E906-E912.
76. Ijaz S, Winslet MC, Seifalian AM. The effect of consecutively larger doses of L-arginine on hepatic microcirculation and tissue oxygenation in hepatic steatosis. Microvasc Res. 2009;78(2):206-211.
77. Ijaz S, Yang W, Winslet MC, Seifalian AM. The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis. Microvasc Res. 2005;70(3):129-136.
78. Jobgen W, Meininger CJ, Jobgen SC, et al. Dietary L-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J Nutr. 2009;139(2):230-237.
79. Beale MA, Ijaz S, Tedder RS. The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants. J Gen Virol. 2010;91(pt 1):68-73.
80. Nordman S, Ding B, Ostenson CG, et al. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes. 2005;113(5):282-287.
81. Leventhal L, Bodnar RJ. Different central opioid receptor subtype antagonists modify maltose dextrin and deprivation-induced water intake in sham feeding and sham drinking rats. Brain Res. 1996;741(1-2):300-308.
82. Beinborn M, Lee YM, McBride EW, Quinn SM, Kopin AS. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature. 1993;362(6418): 348-350.
83. Uhe AM, Collier GR, O'Dea K. A comparison of the effects of beef, chicken and fish protein on satiety and amino acid profiles in lean male subjects. J Nutr. 1992;122(3):467-472.
84. Houpt KA, Houpt TR, Pond WG. The effect of gastric loads of sugars and amino acids on milk intake of suckling pigs. J Anim Sci. 1983;57(2):413-417.
85. Sureda A, Cordova A, Ferrer MD, Perez G, Tur JA, Pons A. L-citrulline-malate influence over branched chain amino acid utilization during exercise. Eur J Appl Physiol. 2010;110(2):341-351.
86. Devkota S, Layman DK. Protein metabolic roles in treatment of obesity. Curr Opin Clin Nutr Metab Care. 2010;13(4):403-407.
87. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323-341.
88. Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr. 2006;136(1) (suppl):227S-231S.
89. Woods SC, Seeley RJ, Cota D. Regulation of food intake through hypothalamic signaling networks involving mTOR. Annu Rev Nutr. 2008;28:295-311.
90. Norton LE, Layman DK, Bunpo P, Anthony TG, Brana DV, Garlick PJ. The leucine content of a complete meal directs peak activation but not duration of skeletal muscle protein synthesis and mammalian target of rapamycin signaling in rats. J Nutr. 2009;139(6):1103-1109.
91. Norton LE, Layman DK. Leucine regulates translation initiation of protein synthesis in skeletal muscle after exercise. J Nutr. 2006;136(2): 533S-537S.
92. Paddon-Jones D, Sheffield-Moore M, Zhang XJ, et al. Amino acid ingestion improves muscle protein synthesis in the young and elderly. Am J Physiol Endocrinol Metab. 2004;286(3):E321-E328.
93. Cota D, Matter EK, Woods SC, Seeley RJ. The role of hypothalamic mammalian target of rapamycin complex 1 signaling in dietinduced obesity. J Neurosci. 2008;28(28):7202-7208.
94. Cota D, Barrera JG, Seeley RJ. Leptin in energy balance and reward: two faces of the same coin? Neuron. 2006;51(6):678-680.
95. Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science. 2006;312(5775):927-930.
96. Clifton PM, Keogh J. Metabolic effects of high-protein diets. Curr Atheroscler Rep. 2007;9(6):472-478.
97. Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ, Yu YH. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes. 2007;56(6):1647-1654.
98. Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, et al. Dose-dependent satiating effect of whey relative to casein or soy. Physiol Behav. 2009;96(4-5):675-682.
99. Dickerson RN, Boschert KJ, Kudsk KA, Brown RO. Hypocaloric enteral tube feeding in critically ill obese patients. Nutrition. 2002;18(3):241-246.
100. Torre-Villalvazo I, Tovar AR, Ramos-Barragan VE, Cerbon-Cervantes MA, Torres N. Soy protein ameliorates metabolic abnormalities in liver and adipose tissue of rats fed a high fat diet. J Nutr. 2008;138(3):462-468.
101. Allison DB, Gadbury G, Schwartz LG, et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur J Clin Nutr. 2003;57(4):514-522.
102. Deibert P, Konig D, Schmidt-Trucksaess A, et al. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. Int J Obes Relat Metab Disord. 2004;28(10): 1349-1352.
103. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13): 1546-1558.
104. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
105. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007;86(5):1286-1292.
106. Pachikian BD, Neyrinck AM, Deldicque L, et al. Changes in intestinal bifidobacteria levels are associated with the inflammatory response in magnesium-deficient mice. J Nutr. 2010;140(3):509-514.
107. Zhong W, McClain CJ, Cave M, Kang YJ, Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G625-G633.
108. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374-2383.
109. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
110. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
111. Kono H, Fujii H, Asakawa M, et al. Protective effects of mediumchain triglycerides on the liver and gut in rats administered endotoxin. Ann Surg. 2003;237(2):246-255.
112. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723.
113. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87(3):534-538.
114. Woodard GA, Encarnacion B, Downey JR, et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg. 2009;13(7):1198-1204.
115. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42(8):675-682.
116. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651- 659.
117. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46(suppl 2):S104-S111; discussion S144-S151.
118. Whelan K, Judd PA, Preedy VR, Simmering R, Jann A, Taylor MA. Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr. 2005;135(8):1896-1902.
119. Whelan K, Judd PA, Tuohy KM, Gibson GR, Preedy VR, Taylor MA. Fecal microbiota in patients receiving enteral feeding are highly variable and may be altered in those who develop diarrhea. Am J Clin Nutr. 2009;89(1):240-247.
120. Beards E, Tuohy K, Gibson G. Bacterial, SCFA and gas profiles of a range of food ingredients following in vitro fermentation by human colonic microbiota. Anaerobe. 2010;16(4):420-425.
121. Kang X, Zhong W, Liu J, et al. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor- alpha. Hepatology. 2009;50(4):1241-1250.
122. Curiel-Garcia JA, Rodriguez-Moran M, Guerrero-Romero F. Hypomagnesemia and mortality in patients with type 2 diabetes. Magnes Res. 2008;21(3):163-166.
123. Geliebter A, Torbay N, Bracco EF, Hashim SA, Van Itallie TB. Overfeeding with medium-chain triglyceride diet results in diminished deposition of fat. Am J Clin Nutr. 1983;37(1):1-4.
124. Lieber CS, DeCarli LM, Leo MA, et al. Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH. J Hepatol. 2008;48(2):318-326.